Anne Wojcicki, the CEO and a co-founder of 23andMe, tells Nature's Soapbox Science blog that her company is moving toward working with pharmaceutical companies on phase 4, post-marketing studies. The company's database contains data from about 150,000 customers, the blog adds. "We definitely want to connect more and more with pharma partners to leverage the platform we've created," Wojcicki says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.